WSTAM
SIOX

Wilbanks Smith & Thomas Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13
Closed – – 1405
2018
Q3 		$0 Buy
+13
New +$237 ﹤0.01% 1628

Other funds holding SIOX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's SIOX Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 13 shares.

Wilbanks Smith & Thomas Asset Management first reported a position in SIOX in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 13 Sio Gene Therapies Inc. Common Stock shares in Q4 2018.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $0 in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.